Navigation Links
Encision Reports 14% Revenue Increase in Second Quarter Results
Date:10/24/2011

BOULDER, Colo., Oct. 24, 2011 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its second fiscal quarter ended September 30, 2011.

The Company recorded a net loss of $469,000 or $(0.07) per share for the second quarter of fiscal year 2012 on net product revenue of $2.830 million and net service revenue of $437 thousand. Total revenue of $3.267 million represented a 14% increase from total revenue of $2.866 million for the second quarter of fiscal year 2011. The Company recorded a $145,000 net loss, or $(0.02) per share for the second quarter of fiscal year 2011. The net loss of $469,000 for the second quarter of fiscal year 2012 included approximately $500,000 of one-time charges. The one-time charges were $430,000 for a voluntary recall of certain electrode product, as announced in the Company's press release of October 17, 2011, and separation expense for the Company's former President and CEO.

Gross profit margin, on total revenue, for the second quarter of fiscal year 2012 was 48% as compared to 64% for the second quarter of fiscal year 2011. The gross profit margin decrease from the second quarter of fiscal year 2011 was due to the charge for a voluntary recall, as explained above, and an increase, as a percentage of revenue, of lower gross margin revenue. Excluding the voluntary recall cost, gross profit margin for the second quarter of fiscal year 2012 was 61%.

The Company recorded a net loss of $490,000 or $(0.08) per share for the first six months ended September 30, 2011 on net product revenue of $5.664 million and net service revenue of $787 thousand. Total revenue of $6.451 million represented a 12% increase from total revenue of $5.778 million for the first six months ended September 30, 2010. The Company recorded a $264,000 net loss, or $(0.04) per share for the first six months ended September 30, 2010.

Gross profit margin, on total revenue, for the first six months ended September 30, 2011 was 52% as compared to 64% for the first six months ended September 30, 2010. The gross profit margin decrease from the first six months ended September 30, 2010 was due to the items that were explained above.

"Although the Company has suffered a setback due to the recall, we will continue to maintain our devotion to producing quality instruments for our customers," said Fred Perner, Encision's new President and CEO.  "Our mission includes the improvement of patient outcomes and the enhancement of patient safety. A culture of quality is paramount to achieving that mission. In my short time here, I have witnessed the commitment that our employees have to that culture and have personally seen what our technology means to surgeons and patients."

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:   Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.comEncision Inc.Condensed Balance Sheets(Amounts in thousands)(Unaudited)September 30,2011March 31, 2011ASSETSCash and cash equivalents$
5$
20Accounts receivable, net1,1011,160Inventories, net2,6892,604Prepaid expenses12274Total current assets3,9273,958Equipment, net1,3811,169Patents, net269260Other assets124Total assets$ 5,578$ 5,411LIABILITIES AND SHAREHOLDERS' EQUITYAccounts payable$
728$
74Accrued compensation233261Other accrued liabilities617287Line of credit691435Total current liabilities2,2691,657Common stock and additional paid-in capital19,82819,783Accumulated (deficit)(16,519)(16,029)Total shareholders' equity3,3093,754Total liabilities and shareholders' equity$ 5,578$  5,411Encision Inc.Condensed Statements of Operations(Amounts in thousands, except per share information)(Unaudited)Three Months EndedSix Months EndedSeptember 30,2011September 30,2010September 30,2011September 30,2010Net revenue:Product$ 2,830$ 2,866$ 5,664$ 5,729Service437––78749Total revenue3,2672,8666,4515,778Cost of revenue:Product1,5251,0322,7862,055Service176––32045Total cost of revenue1,7011,0323,1062,100Gross profit1,5661,8343,3453,678Operating expenses:Sales and marketing1,2131,0752,2502,261General and administrative463397882793Research and development342495673867Total operating expenses2,0181,9673,8053,921Operating loss(452)(133)(460)(243)Interest and other income (expense), net(17)(12)(30)(21)Loss before provision for income taxes(469)(145)(490)(264)Provision for income taxes––––––––Net loss$  (469)$   (145)$
(490)$   (264)Net loss per share—basic and diluted$ (0.07)$ (0.02)$   (0.08)$ (0.04)Basic  and diluted weighted average number of shares6,4556,4556,4556,455
'/>"/>

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Encision Reports Profitable Third Fiscal Quarter Results
2. Encision and HealthTrust Purchasing Group Sign Purchasing Agreement
3. Encisions Technology Recognized as A Means to Eliminate Surgery Burns
4. Encisions Active Electrode Monitoring Technology Recommended at Minimally Invasive Gynecology Congress
5. Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results
6. Encision Reports 9.3% Revenue Increase in First Quarter Results
7. Encision Announces Leadership Change
8. Encision Announces Voluntary Recall of Certain Electrode Product
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):